FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990094600> ?p ?o ?g. }

• W2990094600 endingPage "861" @default.
• W2990094600 startingPage "861" @default.
• W2990094600 abstract "Introduction: Carfilzomib (20/36mg/m2) triplets with Lenalidomide-Dexamethasone (KRd), or Cyclophosphamide-Dexamethasone (KCd) are safe and effective in patients with newly diagnosed multiple myeloma(NDMM). The higher dose of 56mg/m2 is effective as a doublet with Dexamethasone in the relapsed setting, but there is limited data on this dose in triplet combinations in the frontline setting. Aim: The CARDAMON study evaluated KCd with bi-weekly carfilzomib (56mg/m2) as induction in NDMM patients, and the benefit of ASCT versus K56Cd consolidation followed by carfilzomib maintenance. Co-primary endpoints were major response (≥VGPR rate) to 4 induction cycles of K56Cd, and 2-year PFS for ASCT versus K56Cd consolidation. Here we report interim analysis of the first primary endpoint of ≥VGPR rate to K56Cd induction. Methods: Transplant eligible ND patients received 4 x 28d cycles of K56Cd (carfilzomib:20/56mg/m2, IV d1, 2, 8, 9, 15, 16, cyclophosphamide 500mg orally d1, 8, 15 and dexamethasone 20mg d1, 2, 8, 9, 15, 16). Responding patients with a successful stem cell harvest (PBSCH) were randomised to autologous stem cell transplant (ASCT) or 4 more cycles of K56Cd as consolidation, followed by 18 months carfilzomib maintenance (K56 days 1, 8, 15) for both arms. Trial recruitment completed in July 2019. Response was assessed by IMWG criteria; all patients had MRD testing by multi-parameter flow cytometry (10-5) after PBSCH. Adverse risk genetics was any one of t(4;14), t(14;16), t(14,20) or del(17p). Results: 281 pts were registered between 06/2015 and 07/2019; we report outcomes for 252 patients who either completed induction or came off study before end of induction. Median age was 58yrs(33-74), 91% ECOG 0-1, 45.2% ISS I, 24.7% adverse risk (48.5% when including 1p/1q+). Best response at end of induction or after PBSCH (n=250) was: ≥VGPR 59.2%, ORR 87.6%. ≥VGPR rate in adverse risk patients was 53.4% vs 61.9% in standard risk(SR), (p=0.25), ORR was similar: adverse risk, 87.9% vs standard risk, 88.1%. Post-PBSCH, 24.1% of patients were MRD-negative (patients who were withdrawn due to insufficient induction response or toxicity and those with an inconclusive result were grouped with the MRD-positive). Of 19 patients in sCR/CR, 9 were MRD-negative(47.4%) while 40/110 (36.4%) of VGPR patients were MRD-negative. MRD-negative rates in adverse and standard risk patients were 22.8% and 24.7% respectively. 10 patients progressed during or at end of induction, and 12 were withdrawn for toxicity. There were 4 deaths during induction, one from myocardial infarction, the other 3 from cardiac arrest, associated with bronchopneumonia and sepsis. During induction, 114 serious adverse events (SAEs) were reported in 72/252 patients, notable ones were thrombotic microangiopathy (2), grade 3 cardiac ischaemia (4), infection (16.3%, mainly lung), renal impairment (6), G3 hypertension (3), thromboembolism(2). Specific guidance for hypertension management was incorporated. 25% of patients are currently reported to have received a dose modification during induction. Full details of adverse events and dose intensity will be presented at the meeting. Conclusion: K56Cd is an effective induction regimen in NDMM patients, and has equivalent MRD negative rates in adverse and standard risk disease. The SAE profile is in keeping with published safety data with carfilzomib. Disclosures Yong: Sanofi: Speakers Bureau; Amgen: Research Funding, Speakers Bureau; Autolus: Consultancy; Janssen: Speakers Bureau; Takeda: Research Funding, Speakers Bureau. Popat:Celgene Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel, accommodations, expenses; Janssen: Honoraria, Other: travel support to meetings; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Honoraria; Takeda: Honoraria, Other: travel, accommodations, expenses. Ramasamy:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; NAPP Pharmaceuticals Ltd.: Research Funding; Janssen-Cilag Ltd.: Research Funding; Oncopeptides and Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees. Chapman:Takeda: Honoraria. Benjamin:Allogene: Research Funding; Gilead: Honoraria; Novartis: Honoraria; Pfizer: Research Funding; Amgen: Honoraria; Takeda: Honoraria; Servier: Research Funding; Eusapharm: Consultancy. Owen:Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other: Travel/ meeting support. OffLabel Disclosure: Carfilzomib is used with cyclophosphamide as 1st line treatment for myeloma" @default.
• W2990094600 created "2019-12-05" @default.
• W2990094600 creator A5006423226 @default.
• W2990094600 creator A5021140442 @default.
• W2990094600 creator A5025879031 @default.
• W2990094600 creator A5026520810 @default.
• W2990094600 creator A5026840856 @default.
• W2990094600 creator A5026876598 @default.
• W2990094600 creator A5027793525 @default.
• W2990094600 creator A5028381731 @default.
• W2990094600 creator A5047494868 @default.
• W2990094600 creator A5050819642 @default.
• W2990094600 creator A5062076815 @default.
• W2990094600 creator A5062329233 @default.
• W2990094600 creator A5062426102 @default.
• W2990094600 creator A5063301766 @default.
• W2990094600 creator A5068293508 @default.
• W2990094600 creator A5072918409 @default.
• W2990094600 creator A5073537179 @default.
• W2990094600 creator A5075200393 @default.
• W2990094600 creator A5076765712 @default.
• W2990094600 creator A5081233146 @default.
• W2990094600 creator A5082564837 @default.
• W2990094600 creator A5085697571 @default.
• W2990094600 date "2019-11-13" @default.
• W2990094600 modified "2023-09-28" @default.
• W2990094600 title "Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study" @default.
• W2990094600 doi "https://doi.org/10.1182/blood-2019-127992" @default.
• W2990094600 hasPublicationYear "2019" @default.
• W2990094600 type Work @default.
• W2990094600 sameAs 2990094600 @default.
• W2990094600 citedByCount "7" @default.
• W2990094600 countsByYear W29900946002020 @default.
• W2990094600 countsByYear W29900946002021 @default.
• W2990094600 countsByYear W29900946002022 @default.
• W2990094600 crossrefType "journal-article" @default.
• W2990094600 hasAuthorship W2990094600A5006423226 @default.
• W2990094600 hasAuthorship W2990094600A5021140442 @default.
• W2990094600 hasAuthorship W2990094600A5025879031 @default.
• W2990094600 hasAuthorship W2990094600A5026520810 @default.
• W2990094600 hasAuthorship W2990094600A5026840856 @default.
• W2990094600 hasAuthorship W2990094600A5026876598 @default.
• W2990094600 hasAuthorship W2990094600A5027793525 @default.
• W2990094600 hasAuthorship W2990094600A5028381731 @default.
• W2990094600 hasAuthorship W2990094600A5047494868 @default.
• W2990094600 hasAuthorship W2990094600A5050819642 @default.
• W2990094600 hasAuthorship W2990094600A5062076815 @default.
• W2990094600 hasAuthorship W2990094600A5062329233 @default.
• W2990094600 hasAuthorship W2990094600A5062426102 @default.
• W2990094600 hasAuthorship W2990094600A5063301766 @default.
• W2990094600 hasAuthorship W2990094600A5068293508 @default.
• W2990094600 hasAuthorship W2990094600A5072918409 @default.
• W2990094600 hasAuthorship W2990094600A5073537179 @default.
• W2990094600 hasAuthorship W2990094600A5075200393 @default.
• W2990094600 hasAuthorship W2990094600A5076765712 @default.
• W2990094600 hasAuthorship W2990094600A5081233146 @default.
• W2990094600 hasAuthorship W2990094600A5082564837 @default.
• W2990094600 hasAuthorship W2990094600A5085697571 @default.
• W2990094600 hasConcept C126322002 @default.
• W2990094600 hasConcept C126894567 @default.
• W2990094600 hasConcept C143998085 @default.
• W2990094600 hasConcept C203092338 @default.
• W2990094600 hasConcept C2776063141 @default.
• W2990094600 hasConcept C2776364478 @default.
• W2990094600 hasConcept C2776694085 @default.
• W2990094600 hasConcept C2776755627 @default.
• W2990094600 hasConcept C2779050716 @default.
• W2990094600 hasConcept C2780108899 @default.
• W2990094600 hasConcept C2780401358 @default.
• W2990094600 hasConcept C535046627 @default.
• W2990094600 hasConcept C71924100 @default.
• W2990094600 hasConceptScore W2990094600C126322002 @default.
• W2990094600 hasConceptScore W2990094600C126894567 @default.
• W2990094600 hasConceptScore W2990094600C143998085 @default.
• W2990094600 hasConceptScore W2990094600C203092338 @default.
• W2990094600 hasConceptScore W2990094600C2776063141 @default.
• W2990094600 hasConceptScore W2990094600C2776364478 @default.
• W2990094600 hasConceptScore W2990094600C2776694085 @default.
• W2990094600 hasConceptScore W2990094600C2776755627 @default.
• W2990094600 hasConceptScore W2990094600C2779050716 @default.
• W2990094600 hasConceptScore W2990094600C2780108899 @default.
• W2990094600 hasConceptScore W2990094600C2780401358 @default.
• W2990094600 hasConceptScore W2990094600C535046627 @default.
• W2990094600 hasConceptScore W2990094600C71924100 @default.
• W2990094600 hasIssue "Supplement_1" @default.
• W2990094600 hasLocation W29900946001 @default.
• W2990094600 hasOpenAccess W2990094600 @default.
• W2990094600 hasPrimaryLocation W29900946001 @default.
• W2990094600 hasRelatedWork W1985864219 @default.
• W2990094600 hasRelatedWork W2093665884 @default.
• W2990094600 hasRelatedWork W2515748752 @default.
• W2990094600 hasRelatedWork W2519443088 @default.
• W2990094600 hasRelatedWork W2810979422 @default.
• W2990094600 hasRelatedWork W2892083382 @default.
• W2990094600 hasRelatedWork W2980570729 @default.
• W2990094600 hasRelatedWork W3029900969 @default.
• W2990094600 hasRelatedWork W4245786844 @default.
• W2990094600 hasRelatedWork W4310160996 @default.

• next